Drug Co. Investors Seek OK For Early $3.8M Settlement

Law360, New York (April 17, 2017, 2:55 PM EDT) -- A putative class of investors in Amicus Therapeutics Inc. who said the company’s misleading statements about their interaction with the U.S. Food and Drug Administration amounted to securities fraud asked a New Jersey federal court on Friday to approve a $3.75 million settlement that would end the litigation before the court even considered dismissal.

The shareholders said their deal with Amicus would get them more than 8 percent of the $44 million in damages they say they incurred in the last two weeks of September 2015,...
To view the full article, register now.